doxorubicin hydrochloride / Generic mfg. - LARVOL DELTA

Assessing the efficacy and tolerability of PET-guided BrECADD versus eBEACOPP in advanced-stage, classical Hodgkin lymphoma (HD21): a randomised, multicentre, parallel, open-label, phase 3 trial. (PubMed, Lancet) - P3 | "BrECADD guided by PET after two cycles is better tolerated and more effective than eBEACOPP in first-line treatment of adult patients with advanced-stage, classical Hodgkin lymphoma."

Journal • Metastases • P3 data • Hematological Malignancies • Hodgkin Lymphoma • Lymphoma • Oncology

Doxorubicin-Trabectedin with Trabectedin Maintenance in Leiomyosarcoma. (PubMed, N Engl J Med) - P3 | "Combination therapy with doxorubicin and trabectedin induction, followed by trabectedin maintenance, was associated with improved overall survival and progression-free survival, as compared with doxorubicin alone, among patients with metastatic or surgically unresectable uterine or soft-tissue leiomyosarcoma. (Funded by PharmaMar and others; LMS04 ClinicalTrials.gov number, NCT02997358.)."

Clinical • Journal • Leiomyosarcoma • Oncology • Sarcoma • Solid Tumor

Nivolumab+AVD in Advanced-Stage Classic Hodgkin's Lymphoma. (PubMed, N Engl J Med) - P3 | "N+AVD resulted in longer progression-free survival than BV+AVD in adolescents and adults with stage III or IV advanced-stage classic Hodgkin's lymphoma and had a better side-effect profile. (Funded by the National Cancer Institute of the National Institutes of Health and others; S1826 ClinicalTrials.gov number, NCT03907488.)."

Clinical • Journal • Metastases • Hematological Malignancies • Hodgkin Lymphoma • Lymphoma • Oncology • Pediatrics

Final results of a multicentre pilot study evaluating brentuximab vedotin with cyclophosphamide, doxorubicin, etoposide and prednisone (BV-CHEP) for the treatment of aggressive adult T-cell leukaemia/lymphoma. (PubMed, Br J Haematol) - No abstract available

Journal • Adult T-Cell Leukemia-Lymphoma • Hematological Malignancies • Leukemia • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • T Cell Non-Hodgkin Lymphoma

Neoadjuvant Pembrolizumab and Accelerated Methotrexate, Vinblastine, Doxorubicin, and Cisplatin in Nonurothelial Histologic Subtypes of Muscle-invasive Bladder Cancer: A Phase 2 Trial. (PubMed, Eur Urol) - "These findings suggest that chemoimmunotherapy is a very promising approach for MIBC with histology subtypes. Larger studies are warranted to further refine therapeutic strategies."

IO biomarker • Journal • P2 data • Bladder Cancer • Genito-urinary Cancer • Oncology • Sarcoma • Solid Tumor

DESTINY-Breast11: Neoadjuvant trastuzumab deruxtecan alone (T-DXd) or followed by paclitaxel + trastuzumab + pertuzumab (T-DXd-THP) vs SOC for high-risk HER2+ early breast cancer (eBC) (ESMO 2025) - P3 | "We report neoadjuvant T-DXd or T-DXd-THP vs dose-dense doxorubicin + cyclophosphamide (ddAC)-THP in a phase 3, multicenter, open-label, randomized study. Table: 291O T-DXd-THP ddAC-THP Full analysis set, n 321 320 pCR rate, %* 67.3 56.3 ΔpCR vs ddAC-THP, % (95% CI; P value) † 11.2 (4.0, 18.3; 0.003) − EFS hazard ratio (95% CI) ‡ 0.56 (0.26, 1.17) − Safety analysis set, n 320 312 Any SAE, n (%) 34 (10.6) 63 (20.2) Any AE leading to, n (%) Dose reduction 58 (18.1) 60 (19.2) Dose interruption 121 (37.8) 170 (54.5) Drug discontinuation 45 (14.1) 31 (9.9) Death 2 (0.6) 2 (0.6) Drug-related adjudicated ILD / pneumonitis, n (%) 14 (4.4) 16 (5.1) Grade ≥3 2 (0.6) 6 (1.9) 5 1 (0.3) 1 (0.3) Left ventricular dysfunction, n (%) 6 (1.9) 28 (9.0) Grade ≥3 1 (0.3) 7 (2.2) *By blinded central review † Stratified Miettinen & Nurminen method; P value crossed the 0.03 prespecified boundary ‡ 4.5% maturity Conclusions Neoadjuvant T-DXd-THP demonstrated a clinically meaningful and..."

Clinical • Breast Cancer • HER2 Breast Cancer • HER2 Positive Breast Cancer • Oncology • Solid Tumor • HER-2

5-fluoro-deoxyglucose PET/CT response after neoadjuvant chemotherapy predicts long-term outcomes in soft tissue sarcomas: Results from a prospective trial. (PubMed, Cancer) - "An SUVmax reduction verified on FDG-PET/CT imaging after neoadjuvant chemotherapy was a strong predictor of long-term outcomes. Metabolic imaging at treatment completion identified responders, supporting continued therapy in initially nonresponsive patients and guiding personalized treatment strategies."

Journal • Oncology • Sarcoma • Soft Tissue Sarcoma • Solid Tumor

Low dose pembrolizumab in addition to neoadjuvant anthracycline and taxane in triple-negative breast cancer: A randomized controlled trial (ESMO 2025) - "Patients with untreated stage II-III TNBC without access to standard dose pembrolizumab (SDPm) were randomized (1:1) to receive neoadjuvant dose-dense chemotherapy (4 cycles of doxorubicin and cyclophosphamide followed by 4 cycles of paclitaxel) with or without 50 mg LDPm administered every 6 weeks for 3 cycles. Conclusions The absolute benefit with LDPm appears numerically comparable to that observed with SDPm in the KN522 trial. Therefore, in resource-constrained settings where SDPm is inaccessible, a low-dose alternative strategy may provide a viable treatment option in patients with TNBC."

Clinical • Late-breaking abstract • Breast Cancer • Oncology • Solid Tumor • Triple Negative Breast Cancer

Efficacy and safety of a fully human BCMA CAR T-cell therapy for high-risk newly diagnosed transplant-ineligible multiple myeloma: Updated results from an open label, single-arm,phase 1 study(fumanba-2) (ASH 2025) - P1 | "Pts would undergo 4 cycles ofinduction chemotherapy based on one of three regimens: Bortezomib-Lenalidomide-Dexamethasone,Bortezomib-Cyclophosphamide-Dexamethasone, or Bortezomib-Adriamycin-Dexamethasone...After lymphodepletion with Fludarabine-Cyclophosphamide, pts received a single infusion of Eque-cel at the dose of 1.0 x 106 CAR-T cells/Kg.Primary endpoint was the proportion of minimal residual disease (MRD)-negative (MRD−; sensitivity <10-5) and progression-free survival (PFS)...Soluble BCMA was cleared within 1 month post infusion in 81.25% (13/16) of pts.Secretion of inflammatory cytokines was also observed, with median peak levels of 58.59 pg/mL (range:9.12-3017.83 pg/mL) for IL-6, 44.30 mg/L (range: 3.66-117.30 mg/L) for CRP, and 553.35 ng/mL (range:68.10-2349.00 ng/mL) for ferritin.In conclusion, the current data suggest that Eque-cel could be a promising and effective treatment optionfor high-risk NDMM pts following induction therapy. However, longer..."

CAR T-Cell Therapy • Clinical • P1 data • CNS Disorders • Hematological Disorders • Hematological Malignancies • Infectious Disease • Influenza • Multiple Myeloma • Novel Coronavirus Disease • Pneumonia • Respiratory Diseases • Transplantation • IL6

Clinical prognostication in the SWOG 1826 randomized clinical trial of nivolumab-AVD versus brentuximab-AVD: Performance of the advanced-stage Hodgkin lymphoma international prognostic index (A-HIPI) (ASH 2025) - "The phase 3 randomized SWOG S1826 study, the largest National Clinical Trials Network study of AS cHL,compared nivolumab with doxorubicin, vinblastine, and dacarbazine (N+AVD) with brentuximab vedotinwith doxorubicin, vinblastine, and dacarbazine (BV+AVD) in pts 12 yrs or older with AS newly diagnosedcHL. This refined prediction model, which leverages continuous datavalues, is poised to serve as the new standard for risk stratification for adults with AS cHL. Funding NIH/NCI grant awards U10CA180888, U10CA180819, R01CA262265-04"

Clinical • Metastases • Classical Hodgkin Lymphoma • Hematological Malignancies • Hodgkin Lymphoma • Lymphoma

3-year follow-up of the S1826 study confirms improved progression-free survival with nivolumab-AVD compared to brentuximab vedotin-AVD in advanced stage classic Hodgkin lymphoma (ASH 2025) - "Introduction: The randomized phase 3 S1826 study demonstrated that, in adolescent and adult patients(pts) with previously untreated advanced stage (AS) classic Hodgkin lymphoma (cHL), PD-1 blockade withnivolumab in combination with doxorubicin, vinblastine, and dacarbazine (N-AVD) prolongedprogression-free survival (PFS) compared with standard brentuximab vedotin (BV) combined with AVD ata median follow-up of 2 years. The benefit of N-AVD compared to BV-AVD in adolescent and adult pts with AS cHL issustained with 3y follow-up, including all pre-specified age, stage, and IPS risk subgroups. This updatedemonstrates the durability of remissions with N-AVD over time without any new safety signals, andenables benchmarking with other modern cHL trials. Follow-up will continue to evaluate for latetoxicities, OS, and PROs."

Metastases • Classical Hodgkin Lymphoma • Genetic Disorders • Hematological Malignancies • Hodgkin Lymphoma • Lymphoma • Multiple Myeloma • Non-Hodgkin’s Lymphoma • Skin Cancer • Solid Tumor

Primary Results from the HR+/HER2- Cohort of TBCRC-053 (P-RAD): A Randomized Trial of No, Low, or High Dose Preoperative RADiation with Pembrolizumab and Chemotherapy in Node-Positive, HER2-Negative Breast Cancer (SABCS 2025) - P2 | "Patients subsequently received pembrolizumab with 12 weeks of paclitaxel, followed by 4 cycles of adriamycin-cyclophosphamide (q2wk or q3wk) with pembrolizumab (200 mg q3 wks or 400 mg q6 wks). The addition of 24Gy preop RT to aPD1 significantly increased tumor TCI in HR+/HER2- early-stage BC. Non-irradiated nodal response rates were promising despite over one-third of the study population with grade 1/2 tumors and high disease burden, laying the foundation for a future randomized trial comparing the efficacy of this novel approach against standard of care for node-positive HR+/HER2- BC."

Clinical • IO biomarker • Breast Cancer • HER2 Breast Cancer • HER2 Negative Breast Cancer • HER2 Positive Breast Cancer • Hormone Receptor Breast Cancer • Hormone Receptor Positive Breast Cancer • CD8 • HER-2 • PGR

Effects of antibiotic prophylaxis in first-line therapy of advanced stage classic Hodgkin lymphoma: An analysis of the GHSG HD21 study (ASH 2025) - "In the GHSG HD21 trial for advanced-stage classic Hodgkin lymphoma (AS-cHL), patients received polychemotherapy regimens (eBEACOPP[bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone] orBrECADD [brentuximab vedotin, etoposide, cyclophosphamide, doxorubicin, dacarbazine, anddexamethasone]) with a risk to develop febrile neutropenia (FN) and/or infections. This comprehensive analysis of the HD21 trial demonstrates the efficacy of ABP and peg G-CSF in thetreatment of AS-cHL in preventing FN and higher-grade infections. This effect is most pronounced in thefirst cycle and in patients receiving BrECADD. Based on these results, we recommend the use of ABPduring the first cycle of the BrECADD regimen, at least."

Clinical • Metastases • Classical Hodgkin Lymphoma • Febrile Neutropenia • Hematological Malignancies • Hodgkin Lymphoma • Infectious Disease • Lymphoma • Neutropenia

Cemiplimab in High-risk or Locally Advanced Luminal and Triple Negative Breast Cancer (CemiHALT) (SABCS 2025) - P2 | "Pts were treated with standard taxane and anthracycline-based NACT (weekly paclitaxel x 12 with carboplatin added for TNBC only, followed by adriamycin and cyclophosphamide x 4 cycles)...The trial was later amended to incorporate cemiplimab concurrently throughout NACT for TNBC pts after FDA approval of neoadjuvant pembrolizumab per KEYNOTE-522 in July 2021... Addition of cemiplimab to NACT resulted in 23% pCR rate in the overall cohort with a significantly higher pCR (50%) seen in TNBC pts. Baseline PD-L1 and/or PD-L2 expression was not associated with pCR rates or radiographic responses. This study incorporated only 2 doses of cemiplimab for ER+ pts which could explain the low pCR rates in this cohort."

IO biomarker • Metastases • Breast Cancer • Estrogen Receptor Positive Breast Cancer • HER2 Breast Cancer • HER2 Negative Breast Cancer • HER2 Positive Breast Cancer • Hormone Receptor Breast Cancer • Oncology • Solid Tumor • Triple Negative Breast Cancer • ER • HER-2 • PD-L1 • PD-L2

Patient-reported outcomes (PROs) in DESTINY-Breast11: neoadjuvant treatment (NAT) with trastuzumab deruxtecan (T-DXd) alone or followed by paclitaxel + trastuzumab + pertuzumab (THP) vs dose-dense doxorubicin + cyclophosphamide followed by THP (ddAC-THP) in high-risk, HER2+ early-stage breast cancer (eBC) (SABCS 2025) - "More patients had maintained or improved PF with T-DXd or T-DXd-THP vs ddAC-THP. T-DXd and T-DXd-THP demonstrated a lower patient-reported treatment burden (tolerability, symptomatic AEs) than ddAC-THP. These findings, together with the favorable safety and efficacy profile of T-DXd-THP vs ddAC-THP, support T-DXd-THP as a tolerable therapy in high-risk HER2+ eBC.Table."

Clinical • Patient reported outcomes • Breast Cancer • HER2 Breast Cancer • HER2 Positive Breast Cancer • Oncology • Solid Tumor • HER-2

Epcoritamab monotherapy for Richter transformation (EPCORE CLL-1): findings from a single-arm, multicentre, open-label, phase 1b/2 trial. (PubMed, Lancet Haematol) - P1/2 | "In patients with Richter transformation, epcoritamab monotherapy showed clinically meaningful antitumour activity, although the investigator-assessed overall response rate was below the alternative hypothesis of 50%, with a safety profile consistent with previous studies. These findings support further investigation of epcoritamab as a potential treatment option for patients with Richter transformation."

Journal • Monotherapy • P1/2 data • B Cell Lymphoma • Cardiovascular • Chronic Lymphocytic Leukemia • Diffuse Large B Cell Lymphoma • Hematological Disorders • Hematological Malignancies • Infectious Disease • Leukemia • Lymphoma • Neutropenia • Non-Hodgkin’s Lymphoma • Novel Coronavirus Disease • Oncology • Pneumonia • Respiratory Diseases • Richter's Syndrome • Septic Shock • Small Lymphocytic Lymphoma • Thrombocytopenia • TP53

Safety and Efficacy of Cisplatin and Doxorubicin Pressurized Intraperitoneal Aerosolized Chemotherapy (PIPAC) in Patients with Ovarian Cancer with Peritoneal Metastases: A Multicenter US Phase I Trial. (PubMed, Ann Surg Oncol) - P1 | "PIPAC-CD is feasible, safe, and well tolerated at academic US centers. OS and PFS were limited in patients with heavily pretreated ovarian carcinoma who underwent PIPAC-CD. Future trials should focus on optimizing PIPAC drug combinations and determining optimal patient selection criteria for ovarian cancer."

Journal • P1 data • Anorexia • Oncology • Ovarian Cancer • Pain • Peritoneal Cancer • Solid Tumor

FEASIBILITY AND CLINICAL EFFICACY OF ATEZOLIZUMAB CONSOLIDATION IN HIGH RISK DIFFUSE LARGE B-CELL LYMPHOMA: FINAL ANALYSIS OF THE HOVON 151 (EHA 2024) - "Background: The 2-year disease-free survival (DFS) rate following rituximab, cyclophosphamide, doxorubicin, vincristine, andprednisolone (R-CHOP) in high-risk diffuse large B-cell lymphoma (DLBCL) patients achieving completemetabolic remission (CMR) is 78%. Atezolizumab consolidation therapy demonstrated a significant improvement in DFS for patients with high riskDLBCL compared to historical benchmarks. The remarkable 2-year OS rate of 96. 3% stands out as one of thehighest observed outcomes for high risk DLBCL, with the majority of patients exhibiting chemo-sensitivedisease at relapse."

Clinical • CNS Disorders • Diffuse Large B Cell Lymphoma • Endocrine Disorders • Follicular Lymphoma • Hematological Malignancies • Hodgkin Lymphoma • Immunology • Indolent Lymphoma • Infectious Disease • Lymphoma • Musculoskeletal Diseases • Non-Hodgkin’s Lymphoma • Novel Coronavirus Disease • Oncology • Rheumatology

Combination lurbinectedin and doxorubicin versus physician's choice of chemotherapy in patients with relapsed small-cell lung cancer (ATLANTIS): a multicentre, randomised, open-label, phase 3 trial. (PubMed, Lancet Respir Med) - P3 | "Combination therapy with lurbinectedin plus doxorubicin did not improve overall survival versus control in patients with relapsed SCLC. However, lurbinectedin plus doxorubicin showed a favourable haematological safety profile compared with control."

Journal • P3 data • Hematological Disorders • Lung Cancer • Neuroendocrine Tumor • Neutropenia • Oncology • Small Cell Lung Cancer • Solid Tumor • Thrombocytopenia

NCI-2018-02699: Nivolumab With DA-REPOCH Chemotherapy Regimen in Treating Patients With Aggressive B-Cell Non-Hodgkin's Lymphoma (clinicaltrials.gov) - P2 | N=30 | Active, not recruiting | Sponsor: David Bond, MD | Trial completion date: Dec 2025 ➔ Dec 2026

Trial completion date • B Cell Lymphoma • B Cell Non-Hodgkin Lymphoma • Classical Hodgkin Lymphoma • Diffuse Large B Cell Lymphoma • Hematological Malignancies • High-grade B-cell lymphoma • Hodgkin Lymphoma • Indolent Lymphoma • Lymphoma • Mediastinal B Cell Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • Primary Mediastinal Large B-Cell Lymphoma • BCL2

2-YEAR FOLLOW-UP OF THE S1826 STUDY CONFIRMS IMPROVED PROGRESSION-FREE SURVIVAL WITH NIVOLUMAB-AVD COMPARED TO BRENTUXIMAB VEDOTIN-AVD IN ADVANCED STAGE CLASSIC HODGKIN LYMPHOMA (ISHL 2024) - "We hypothesized that introducing PD-1 blockade with nivolumab in combination with doxorubicin, vinblastine, and dacarbazine (N-AVD) would improve progression-free survival (PFS) over BV-AVD in AS cHL and evaluated this approach in the randomized, phase 3 S1826 study. N-AVD was better tolerated and improved PFS versus BV-AVD in adolescent and adult pts with AS cHL. Longer follow-up confirmed the PFS benefit with N-AVD at 2 y, including pre-specified subgroups. N-AVD is a new standard of care for treatment of AS cHL."

Metastases • Febrile Neutropenia • Gastroenterology • Gastrointestinal Disorder • Hematological Disorders • Hematological Malignancies • Hodgkin Lymphoma • Immunology • Infectious Disease • Lymphoma • Musculoskeletal Pain • Neutropenia • Oncology • Pain • Pediatrics • Pneumonia

Brentuximab Vedotin and Nivolumab in Combination With Chemotherapy for Nonbulky, Early-Stage Classical Hodgkin Lymphoma. (PubMed, Blood) - P2 | "Most patients with early-stage classical Hodgkin lymphoma (cHL) are treated with doxorubicin, bleomycin, vinblastine, and dacarbazine with or without radiation therapy, although studies are now evaluating the incorporation of novel agents paired with abbreviated chemotherapy. Results from this study support the use of BV and nivolumab in combination with limited chemotherapy in patients with non-bulky, early-stage cHL. ClinicalTrials.gov: NCT03646123."

Journal • Classical Hodgkin Lymphoma • Febrile Neutropenia • Hematological Disorders • Hematological Malignancies • Hodgkin Lymphoma • Lymphoma • Neutropenia • Oncology

Low-Dose Nivolumab Plus AVD As Front-Line Therapy for Classical Hodgkin's Lymphoma: Preliminary Results of a Phase 2 Trial (ASH 2024) - P2 | "Objective : We aimed to evaluate the safety and efficacy of low-dose nivolumab in combination with AVD (doxorubicin, vinblastine and dacarbazine) as a first-line treatment for cHL. After two cycles, all patients achieved an objective response, with most attaining a complete metabolic response and continuing with AVD alone. This approach presents a potential strategy for improved treatment efficacy while mitigating financial and biological toxicity, especially in LMICs."

P2 data • Classical Hodgkin Lymphoma • Endocrine Disorders • Febrile Neutropenia • Hematological Disorders • Hematological Malignancies • Hodgkin Lymphoma • Lymphoma • Neutropenia • Oncology • PD-1

The Management of older patients with Hodgkin lymphoma: implications of S1826. (PubMed, Semin Hematol) - P3 | "A recent phase 3 clinical trial (S1826, NCT03907488) led by the North American oncology cooperative groups compared brentuximab vedotin, doxorubicin, vinblastine, and dacarbazine (BV-AVD) with nivolumab, doxorubicin, vinblastine, and dacarbazine (N-AVD). As a result, N-AVD is poised to become a standard of care for older, advanced-stage cHL patients who are fit for full-dose anthracycline-based combination therapy. More studies are needed to continue to improve outcomes for older cHL patients, especially unfit and frail populations."

Journal • Hematological Malignancies • Hodgkin Lymphoma • Lymphoma • Oncology • Pain

Oral paclitaxel, carboplatin, and dostarlimab (OPE/Cb/D) without and with trastuzumab in early-stage, high-risk breast cancer: Results from the neoadjuvant I-SPY 2 TRIAL. (ASCO 2023) - P2 | "Oral paclitaxel and encequidar (OPE) is an oral combination of paclitaxel (P) with a p-glycoprotein pump inhibitor, encequidar, to enhance gastrointestinal (GI) absorption...Treatment included Oral Paclitaxel 205mg/m2 and encequidar 12.9 mg on days 1-3, Carboplatin (Cb) AUC 1.5 on day 1 weekly x 12, and Dostarlimab (D) 500 mg every 3 weeks x 4, followed by doxorubicin/ cyclophosphamide (AC) every 2-3 weeks x 4... OPE/Cb/D graduated in the TN signature with a higher predicted pCR rate compared to control. OPE and D have been, individually, shown to have efficacy in other settings. The lower-than-expected pCR rate and lower irAEs with triplet therapy (taxane, platinum, immune checkpoint inhibitor [ICI]) in TN compared to prior IV chemo + ICI arms on I-SPY 2 suggests a possible interference of OPE with ICI."

Clinical • IO biomarker • Late-breaking abstract • Alopecia • Anemia • Breast Cancer • Endocrine Disorders • Febrile Neutropenia • Gastrointestinal Disorder • Hematological Disorders • HER2 Breast Cancer • Immune Modulation • Infectious Disease • Nephrology • Neutropenia • Oncology • Oral Cancer • Pain • Renal Disease • Solid Tumor • HER-2